Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma

Future Oncology, Ahead of Print.

Source: Future Oncology - July 27, 2023 Category: Cancer & Oncology Authors: Thomas G Martin Deepu Madduri Lida Pacaud Saad Z Usmani Source Type: research